Presidential Symposium I

LINK to Presidential Symposium I 

LINK to STREAM (needs an ESMO registration)

LBA1 - Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

The abstract concludes: There was a clinically meaningful improvement in CNS DFS with osimertinib: 82% reduction in risk of CNS disease recurrence or death. Results support that osimertinib reduces risk of CNS recurrence in the resected EGFRm NSCLC setting.

See also NEJM ORIGINAL ARTICLE

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

Y.‑L. Wu and Others

 

LBA2 - Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study

The abstract concludes: Lorlatinib resulted in a statistically significant and clinically meaningful improvement in PFS vs crizotinib and should be considered a new first-line treatment option for pts with ALK+ NSCLC.

Read also ESMO's Daily Reporter News: 

CROWN Trial Supports Lorlatinib as a Future First-line Standard Treatment in ALK-positive Non-small Cell Lung Cancer

 

696O_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial  

The abstract concludes: N+C demonstrated superior PFS, OS, and ORR v S in 1L aRCC. The safety profile of this combination was manageable and consistent with the known singleagent AE profiles of N and C. These results support N+C as a new CPI+TKI option for aRCC pts.